ERAP1 and neoplasm: For example, patients expressing hyperactive ERAP1 might be likely to mount better responses to overtrimmed tumor-derived epitopes if given ERAP1 inhibitors, and conversely those expressing hypoactive allotypes if given ERAP1 activators.